日期 影响因子
日期:
2020 年 — 2026 年
2020
2021
2022
2023
2024
2025
2026
影响因子:
–

Neutralization and ADCC reveal divergent spike-subdomain targeting across SARS-CoV-2 vaccine platforms in an African cohort.

中和作用和ADCC揭示了非洲人群中不同SARS-CoV-2疫苗平台对刺突蛋白亚结构域的靶向作用存在差异。

期刊:iScience
影响因子:4.1
doi:10.1016/j.isci.2025.114351
Oluka Gerald Kevin, Katende Joseph Ssebwana, Kato Laban, Ankunda Violet, Sembera Jackson, Ejou Peter, Odoch Geoffrey, Namuyanja Angella, Kaleebu Pontiano, Serwanga Jennifer
DCC
SARS-CoV-2
发表日期：2026
文献求助 收藏

Knowledge, perceptions, uptake, and determinants of HPV vaccination, and preferred delivery strategies among out-of-school girls in Masaka, Uganda

乌干达马萨卡失学女童对HPV疫苗的认知、看法、接种情况及决定因素，以及她们偏好的接种策略

期刊:Human Vaccines & Immunotherapeutics
影响因子:
doi:10.1080/21645515.2026.2654928
Kitonsa, Jonathan; Kafeero, Paddy; Ankunda, Violet; Muhumuza, Richard; Mukasa Kibengo, Freddie; Onyango, Martin; Naluyinda, Hadijah; Opoka, Daniel; Ndagire, Maria Teddy; Awino, Esther; Hibombo, Isiimael; Kimbugwe, Geofrey; Ainembabazi, Dorothy; Kasamba, Ivan; Bahemuka, Ubaldo; Lubega, Gloria; Basajja, Vincent; Kusemererwa, Sylvia; Lutaakome, Joseph; Mayanja, Yunia; Mugisha, Joseph; Ruzagira, Eugene
神经科学
发表日期：2026
文献求助 收藏

Geographical Differences in SARS-CoV-2 Antibody Response Dynamics and Neutralisation Profiles to Mild COVID-19: Lessons from a UK-Uganda Comparison.

SARS-CoV-2 抗体反应动态和对轻症 COVID-19 的中和特征的地域差异：来自英国和乌干达的比较经验

期刊:Vaccines
影响因子:3.4
doi:10.3390/vaccines13040336
Kato Laban, Sembera Jackson, Oluka Gerald Kevin, Katende Joseph Ssebwana, Bemanzi Juliana, Ankunda Violet, Ejou Peter, Kurshan Ashwini, Graham Carl, Seow Jeffrey, Doores Katie J, Malim Michael H, Fox Julie M, Kaleebu Pontiano, Serwanga Jennifer
炎症/感染
新冠
发表日期：2025
文献求助 收藏

The subdued post-boost spike-directed secondary IgG antibody response in Ugandan recipients of the Pfizer-BioNTech BNT162b2 vaccine has implications for local vaccination policies

乌干达接种辉瑞-BioNTech BNT162b2疫苗后，加强免疫后针对刺突蛋白的二次IgG抗体反应较弱，这对当地的疫苗接种政策具有重要意义。

期刊:Frontiers in Immunology
影响因子:5.9
doi:10.3389/fimmu.2024.1325387
Ankunda, Violet; Katende, Joseph Ssebwana; Oluka, Gerald Kevin; Sembera, Jackson; Baine, Claire; Odoch, Geoffrey; Ejou, Peter; Kato, Laban; Kaleebu, Pontiano; Serwanga, Jennifer
IgG
免疫/内分泌
发表日期：2024
文献求助 收藏

Sustained S-IgG and S-IgA antibodies to Moderna's mRNA-1273 vaccine in a Sub-Saharan African cohort suggests need for booster timing reconsiderations

撒哈拉以南非洲人群中针对 Moderna mRNA-1273 疫苗的持续性 S-IgG 和 S-IgA 抗体表明，需要重新考虑加强免疫接种时间。

期刊:Frontiers in Immunology
影响因子:5.9
doi:10.3389/fimmu.2024.1348905
Serwanga, Jennifer; Ankunda, Violet; Katende, Joseph Ssebwana; Baine, Claire; Oluka, Gerald Kevin; Odoch, Geoffrey; Nantambi, Hellen; Mugaba, Susan; Namuyanja, Angella; Ssali, Ivan; Ejou, Peter; Kato, Laban; Musenero, Monica; Kaleebu, Pontiano
IgA
IgG
免疫/内分泌
发表日期：2024
文献求助 收藏

Persistent and robust antibody responses to ChAdOx1-S Oxford-AstraZeneca (ChAdOx1-S, Covishield) SARS-CoV-2 vaccine observed in Ugandans across varied baseline immune profiles

在乌干达不同基线免疫特征的人群中，均观察到对牛津-阿斯利康（ChAdOx1-S，Covishield）SARS-CoV-2疫苗ChAdOx1-S的持续且强效的抗体反应。

期刊:PLoS One
影响因子:2.6
doi:10.1371/journal.pone.0303113
Serwanga, Jennifer; Oluka, Gerald Kevin; Baine, Claire; Ankunda, Violet; Sembera, Jackson; Kato, Laban; Katende, Joseph Ssebwana; Odoch, Geoffrey; Auma, Betty Oliver; Gombe, Ben; Musenero, Monica; Kaleebu, Pontiano
SARS-CoV-2
免疫/内分泌
发表日期：2024
文献求助 收藏

Sustained spike-specific IgG antibodies following CoronaVac (Sinovac) vaccination in sub-Saharan Africa, but increased breakthrough infections in baseline spike-naive individuals

在撒哈拉以南非洲地区接种科兴疫苗后，可产生持续的刺突蛋白特异性IgG抗体，但基线未接种过刺突蛋白疫苗的人群中突破性感染发生率增加。

期刊:Frontiers in Immunology
影响因子:5.9
doi:10.3389/fimmu.2023.1255676
Sembera, Jackson; Baine, Claire; Ankunda, Violet; Katende, Joseph Ssebwana; Oluka, Gerald Kevin; Akoli, Christine Hermilia; Kato, Laban; Odoch, Geoffrey; Ejou, Peter; Opio, Solomon; Musenero, Monica; Kaleebu, Pontiano; Serwanga, Jennifer
炎症/感染
IgG
发表日期：2023
文献求助 收藏

Seroprevalence and durability of antibody responses to AstraZeneca vaccination in Ugandans with prior mild or asymptomatic COVID-19: implications for vaccine policy

乌干达既往感染过轻症或无症状新冠肺炎患者接种阿斯利康疫苗后抗体反应的血清阳性率和持久性：对疫苗政策的启示

期刊:Frontiers in Immunology
影响因子:5.9
doi:10.3389/fimmu.2023.1183983
Serwanga, Jennifer; Baine, Claire; Mugaba, Susan; Ankunda, Violet; Auma, Betty Oliver; Oluka, Gerald Kevin; Kato, Laban; Kitabye, Isaac; Sembera, Jackson; Odoch, Geoffrey; Ejou, Peter; Nalumansi, Amina; Gombe, Ben; Musenero, Monica; Kaleebu, Pontiano
肺炎
新冠
炎症/感染
微生物学
发表日期：2023
文献求助 收藏

Rapid, early, and potent Spike-directed IgG, IgM, and IgA distinguish asymptomatic from mildly symptomatic COVID-19 in Uganda, with IgG persisting for 28 months.

在乌干达，快速、早期且强效的针对刺突蛋白的 IgG、IgM 和 IgA 可区分无症状 COVID-19 患者和轻症 COVID-19 患者，其中 IgG 可持续 28 个月

期刊:Frontiers in Immunology
影响因子:5.9
doi:10.3389/fimmu.2023.1152522
Serwanga Jennifer, Ankunda Violet, Sembera Jackson, Kato Laban, Oluka Gerald Kevin, Baine Claire, Odoch Geoffrey, Kayiwa John, Auma Betty Oliver, Jjuuko Mark, Nsereko Christopher, Cotten Matthew, Onyachi Nathan, Muwanga Moses, Lutalo Tom, Fox Julie, Musenero Monica, Kaleebu Pontiano
信号转导
IGM
IgG
发表日期：2023
文献求助 收藏

Optimisation and Validation of a conventional ELISA and cut-offs for detecting and quantifying anti-SARS-CoV-2 Spike, RBD, and Nucleoprotein IgG, IgM, and IgA antibodies in Uganda.

在乌干达优化和验证常规 ELISA 以及检测和定量抗 SARS-CoV-2 刺突蛋白、RBD 和核蛋白 IgG、IgM 和 IgA 抗体的临界值

期刊:Frontiers in Immunology
影响因子:5.9
doi:10.3389/fimmu.2023.1113194
Oluka Gerald Kevin, Namubiru Patricia, Kato Laban, Ankunda Violet, Gombe Ben, Cotten Matthew, Musenero Monica, Kaleebu Pontiano, Fox Julie, Serwanga Jennifer
炎症/感染
新冠
IGM
IgG
发表日期：2023
文献求助 收藏